Resumen de Investigación
Analyzed using Evidence Intelligence™

Intensive multifactorial therapy reduces mortality risk in women with diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Última actualización 6 de julio de 2026

Key finding

The reduction in mortality risk by MT was greater in women (44% versus 12%, P = 0.019).

This study analyzed the effects of Multifactorial Therapy (MT) versus Usual Care (UC) in participants with type 2 diabetes, finding significant reductions in major adverse cardiovascular events and all-cause mortality.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

High Risk

Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study analyzed the effects of Multifactorial Therapy (MT) versus Usual Care (UC) in participants with type 2 diabetes, finding significant reductions in major adverse cardiovascular events and all-cause mortality.

Clinical relevance

These findings highlight the potential of Multifactorial Therapy in improving health outcomes for individuals with type 2 diabetes, especially among women. By reducing both cardiovascular events and mortality, MT could lead to better long-term health and quality of life for this population.

Keep in mind

The study was a post-hoc analysis, which may limit the strength of conclusions. Results may not be generalizable to all populations with type 2 diabetes. Effectiveness measures were unclear for some outcomes.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Roberto M, Vittorio S, Luca DN, et al. Post-hoc analysis of the Nephropathy In Diabetes type 2 study. Cardiovascular Diabetology. 2024;23:285. doi:10.1186/s12933-024-02371-3

View DOIView on PubMedView on PMC

Efectos Principales

MT reduced the risk of major adverse cardiovascular events by 52% in women and 44% in men (P = 0.11).

MT led to a 44% reduction in all-cause mortality for women compared to 12% for men (P = 0.019).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Multifactorial Therapy (MT), Usual care and All-cause mortality, Cardiovascular events.

This study contributes evidence to

Intervention

Multifactorial Therapy (MT)

Outcome

All-cause mortality

Evidence topic

Cardiovascular Risk

Primary intervention

Multifactorial Therapy (MT)

Primary outcomes

  • All-cause mortality
  • Cardiovascular events

Evidence topics

Cardiovascular Risk

Primary intervention

Multifactorial Therapy (MT)

Primary outcomes

All-cause mortalityCardiovascular events

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 59

1

Related topics

4

Evidence pairs

39

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 4 evidence relationships
  • Includes primary outcome data
  • Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Tema de evidencia

Cardiovascular Risk

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

All-cause mortality

Multifactorial Therapy (MT) → All-cause mortality

Multifactorial Therapy (MT) → All-cause mortality

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Cardiovascular events

Multifactorial Therapy (MT) → Cardiovascular events

Multifactorial Therapy (MT) → Cardiovascular events

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

All-cause mortality

Usual care → All-cause mortality

Usual care → All-cause mortality

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Cardiovascular events

Usual care → Cardiovascular events

Usual care → Cardiovascular events

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Build your personal Evidence Workspace

Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

evidence suggest

La Evidencia Sugiere

  • MT reduced MACE risk by 52% in women and 44% in men.
  • MT decreased all-cause mortality risk by 44% in women compared to 12% in men.
who this applies

A quién se aplica

  • Adults diagnosed with type 2 diabetes.
  • Individuals at risk for cardiovascular events.
keep in mind

Tener en Cuenta

  • The findings are based on a specific study population and may not apply broadly.
  • The statistical significance of some outcomes was not strong (P = 0.11).
  • Further research is needed to confirm these findings in diverse populations.
between the lines

Entre Líneas

  • The study was a post-hoc analysis, which may limit the strength of conclusions.
  • Results may not be generalizable to all populations with type 2 diabetes.
  • Effectiveness measures were unclear for some outcomes.

Save this study

Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on Multifactorial Therapy (MT) and Cardiovascular Outcomes, Multifactorial Therapy (MT) and Cardiovascular Outcomes.

Relaciones de evidencia relacionadas

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Multifactorial Therapy (MT) improve all-cause mortality?

Emerging Evidence

Multifactorial Therapy (MT) appears to improve All-cause mortality.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Multifactorial Therapy (MT) improve cardiovascular events?

Emerging Evidence

Current evidence does not show a clear benefit of Multifactorial Therapy (MT) for Cardiovascular events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Cardiovascular events

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Usual care improve all-cause mortality?

Emerging Evidence

Current evidence does not show a clear benefit of Usual care for All-cause mortality.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Usual care improve cardiovascular events?

Emerging Evidence

Current evidence does not show a clear benefit of Usual care for Cardiovascular events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Cardiovascular events

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Multifactorial Therapy (MT) and Cardiovascular eventsAll studies on Usual care and Cardiovascular eventsAll studies on Multifactorial Therapy (MT) and All-cause mortalityAll studies on Usual care and All-cause mortality

Related research

Read related research summaries.

Digital intervention improves glycemic control in type 2 diabetes patientsTelemonitoring improves glycemic control in pediatric diabetesCHIP improves health outcomes in adults with type 2 diabetesPeer-Created Videos Improve Psychological Outcomes in Type 1 DiabetesDiabetes APP may improve blood glucose control in T2DM patients

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.